Globus Medical, Inc. $GMED Stock Bought by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH lifted its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 6.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 451,403 shares of the medical device company’s stock after acquiring an additional 26,527 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned approximately 0.34% of Globus Medical worth $33,810,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its holdings in Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after acquiring an additional 328,217 shares during the last quarter. Sculptor Capital LP increased its position in Globus Medical by 1.9% during the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares during the period. Madison Avenue Partners LP increased its position in Globus Medical by 3.0% during the 4th quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company’s stock valued at $229,167,000 after purchasing an additional 76,588 shares during the period. Dimensional Fund Advisors LP raised its holdings in Globus Medical by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after purchasing an additional 33,976 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Globus Medical by 2.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company’s stock worth $97,557,000 after purchasing an additional 30,412 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors.

Globus Medical Trading Down 0.0%

Shares of Globus Medical stock opened at $76.30 on Thursday. The company has a market capitalization of $10.24 billion, a P/E ratio of 19.51, a price-to-earnings-growth ratio of 1.23 and a beta of 0.96. The stock has a fifty day simple moving average of $78.82 and a 200 day simple moving average of $81.52. Globus Medical, Inc. has a 12-month low of $57.67 and a 12-month high of $101.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business’s revenue was up 5.9% on a year-over-year basis. During the same period last year, the business earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, analysts predict that Globus Medical, Inc. will post 4.99 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Stifel Nicolaus dropped their price target on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research report on Wednesday, July 8th. Royal Bank Of Canada reduced their price objective on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday, October 1st. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research report on Friday, September 18th. Finally, BMO Capital Markets began coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $99.46.

Insider Buying and Selling at Globus Medical

In related news, Director Stephen T. Zarrilli sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director James Tobin sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the transaction, the director owned 15,000 shares in the company, valued at approximately $1,118,700. This trade represents a 66.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 18.38% of the company’s stock.

About Globus Medical

Globus Medical, Inc is a medical device company that develops musculoskeletal solutions for surgeons, hospitals and ambulatory surgery centers. Its primary focus is the design, development and commercialization of products used in spinal surgery, including implants, instruments, navigation systems and robotic-assisted technologies.

The company’s portfolio includes the ExcelsiusGPS robotic navigation platform, Excelsius3D imaging technology, spinal implants and systems for procedures such as deformity correction, degenerative spine treatment and minimally invasive surgery.